{"type":"trials","record":{"id":87113,"source_id":"isrctn","external_id":"ISRCTN22122298","title":"Using direct observation of dying retinal cells technique to predict the likelihood of macular atrophy developing in newly diagnosed wet macular degeneration patients","brief_summary":"1. To investigate the use of Detection of Apoptosing Retinal Cells (DARC) as a biomarker to predict the onset of macular atrophy (MA) in patients with treatment naïve wet age-related macular degeneration (AMD), who undergo anti-VEGF treatment with absent macular atrophy at baseline. The primary outcome is the development of MA at 12 months and the objective of this study is to establish whether the DARC convolutional neural network (CNN) score at baseline and its change at months 3 and 6 from baseline can predict this outcome. Time frame: at baseline, 3 months, 6 months and 12 months. 2. To assess the correlation between known precursors of MA on fundus autofluorescence (FAF), optical coherence tomography (OCT) and DARC 3. To assess the correlation between response to treatment (anatomical and visual) and change in DARC signal from baseline at months 3, 6 and 12 4. To assess the safety of intravenous administration of ANX776 performed at baseline, month 3 and month 6","overall_status":"Recruiting","phases":["Not Applicable"],"study_type":"Observational","sponsor":"Imperial College London","enrollment":0,"countries":["United Kingdom","England"],"start_date":"2022-01-03","completion_date":"2027-12-31","last_update_date":"2026-01-14","source_url":"https://www.isrctn.com/ISRCTN22122298","editorial_summary":"A registered Not Applicable study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T03:46:39.792962+00:00","last_seen_at":"2026-09-25T03:46:39.551+00:00","metadata":{"sex":"All","age_range":"Mixed","comparator":null,"attribution":"Source: ISRCTN ISRCTN22122298; retrieved 2026-09-25","interventions":["ANX776","Drug"],"reuse_license":"Registry contribution CC BY 4.0; generated metadata CC0","registry_source":"ISRCTN","outcome_measures":["1. Macular atrophy development measured using the DARC CNN score at baseline, 3 and 6 months 2. Presence of MA measured…","1. Development of MA measured using OCT and FAF morphological biomarkers at 12 months 2. Prognostic value of CNN DARC s…"],"design_description":"Observational","source_has_results":false},"controlled_terms":["Age-related macular degeneration and macular atrophy","DARC dye (0.4 mg ANX776) is administered as an intravenous contrast agent for retinal imaging. The Detection of Apoptos…","ANX776","Drug"],"relevance_confidence":100,"source_quality_score":98,"freshness_score":85,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T03:46:42.633202+00:00","duplicate_cluster_key":"id:isrctn22122298","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2022-01-03 to 2027-12-31","comparator":null,"confidence":"structured-source","population":"All · Mixed","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T03:46:39.564Z","intervention":["ANX776","Drug"],"participants":0,"study_design":"Observational","subject_scope":"Human clinical study registration","evidence_stage":"Not Applicable","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["1. Macular atrophy development measured using the DARC CNN score at baseline, 3 and 6 months 2. Presence of MA measured…","1. Development of MA measured using OCT and FAF morphological biomarkers at 12 months 2. Prognostic value of CNN DARC s…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as Observational."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ISRCTN Registry","homepage_url":"https://www.isrctn.com/"}},"canonical_url":"https://www.immortal.life/trials/87113","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}